FDA Drug Shortage Notification System Overhaul Targets Peptide API Supply Transparency

Background: Why Shortage Reporting Reform Was Needed

The COVID-19 pandemic exposed significant gaps in the pharmaceutical supply chain's visibility and resilience, with shortage-related disruptions affecting everything from hospital formularies to outpatient prescription access. Peptide drugs, which include insulin analogs, GLP-1 agonists, antimicrobial peptides, and numerous other therapeutics, proved particularly vulnerable to supply disruptions because their manufacturing requires specialized equipment and expertise that cannot be rapidly scaled or redirected.

Congress responded with the Food and Drug Omnibus Reform Act, which included provisions directing FDA to strengthen shortage notification requirements and develop more proactive shortage prevention mechanisms. The regulations implementing these provisions have been finalized and are now taking effect, with the peptide drug sector facing some of the most significant compliance changes given its combination of complex manufacturing requirements and high shortage risk profile.

Extended Advance Notification Window

The most immediately impactful change for peptide manufacturers is the extension of the advance shortage notification window from three months to six months. Under the previous framework, manufacturers were required to notify FDA of anticipated shortages or market withdrawals at least 180 days before the shortage was expected to occur, a requirement that proved inadequate for peptide drugs, where supply disruptions often become apparent far earlier but notifications came late.

The new six-month window is calculated from the date when the manufacturer first has knowledge or reasonable belief that a shortage may occur, rather than from the projected shortage date itself. This "earliest knowledge" trigger significantly expands the circumstances under which a notification obligation arises, as manufacturers must now report based on emerging supply risks, not confirmed shortages.

For peptide API manufacturers, this means that events such as unanticipated yield failures in synthesis campaigns, equipment malfunctions affecting critical steps, supplier disruptions affecting amino acid raw materials, or quality incidents requiring investigations must be assessed for potential shortage impact and reported to FDA much earlier in the assessment process.

Strategic Reserve Requirements

The new regulations introduce formal strategic inventory reserve requirements for manufacturers of drugs on the Essential Medicine List or those with a demonstrated shortage history. A significant number of peptide drugs fall into one or both categories, as peptide therapeutics appear prominently on essential medicine frameworks and several peptide drug classes have experienced supply challenges in recent years.

The 90-day strategic reserve requirement is calculated based on the average commercial demand from the preceding 12 months. Manufacturers are required to maintain documentation of their reserve levels as part of their standard operating procedures, with reserve status subject to FDA inspection and review.

The reserve requirements create practical operational challenges for peptide manufacturers. Peptide APIs and finished drug products are often temperature-sensitive, with defined shelf-life profiles that must be managed to ensure that reserve inventory does not expire before it is needed. Some peptide formulations, particularly lyophilized products and complex conjugates, have shelf lives that make maintaining a 90-day reserve challenging without continuous production and rotation.

FDA has indicated in guidance that the reserve requirement applies to commercial quantities held anywhere in the distribution chain controlled by the manufacturer, including safety stock maintained at CDMOs under long-term supply agreements. This broader definition of reserve-eligible inventory gives manufacturers flexibility in how they structure their inventory positions.

Electronic Reporting System Modernization

The Drug Shortage Reporting System (DSRS) overhaul represents a significant operational change for manufacturers' regulatory affairs and quality teams. The new system replaces the previous email-based shortage notification process with a structured electronic submission system that requires standardized data fields and automated acknowledgment workflows.

The DSRS requires manufacturers to report a standardized set of information for each shortage notification:

• Specific product identifier (NDA/ANDA number, active ingredient, strength, dosage form, container/closure)
• Anticipated shortage start date and expected duration
• Root cause category (API supply, manufacturing failure, regulatory hold, force majeure, commercial decision)
• Estimated volume impact (percentage of normal supply volume affected)
• Mitigation actions in progress or planned
• Contact information for FDA follow-up

For peptide drugs with complex supply chains involving multiple API suppliers and CDMOs, the root cause reporting requirement may require coordination across multiple parties to provide accurate information. Manufacturers should ensure their shortage reporting procedures address this multi-party information gathering requirement.

Phase III Clinical Trial Drug Coverage Expansion

A significant expansion in the regulations is the extension of shortage notification requirements to investigational drug products when the same active pharmaceutical ingredient is also approved and marketed as a commercial product. This expansion primarily affects the GLP-1 agonist space, where the same peptide APIs used in commercial products are also being studied in clinical trials for new indications or formulations.

For manufacturers of GLP-1 agonists and other commercially marketed peptide drugs with active clinical programs, a supply disruption affecting the API could simultaneously create obligations under both the commercial shortage reporting framework and the new clinical trial drug reporting requirement. This creates a need for coordinated shortage assessment and reporting processes that span the commercial and clinical organizations.

Civil Penalty Enforcement Changes

FDA's authority to impose civil monetary penalties for failure to report anticipated drug shortages existed under prior law but was rarely used due to evidentiary challenges in demonstrating willful non-compliance. The new implementing regulations establish clearer presumptions and streamlined enforcement processes that are expected to result in more active use of civil penalty authority.

Penalties for first violations are set at up to $500,000 per violation, with increased penalties for continuing or repeat violations. The regulations define each day of non-compliance as a separate violation for manufacturers that were required to report but failed to do so, meaning that extended non-reporting can result in substantial aggregate penalty exposure.

For peptide manufacturers, the elevated enforcement environment means that shortage risk assessment needs to be a formal, documented process, not an informal judgment call made by supply chain or manufacturing leadership. Manufacturers should have written procedures for shortage risk assessment that trigger regulatory affairs review when specified thresholds are reached.

Integration with FDA Inspection Prioritization

FDA's Office of Pharmaceutical Quality has announced plans to integrate shortage risk signals from the DSRS into its inspection prioritization framework for peptide manufacturers. Under this approach, manufacturers with products on the active shortage list, manufacturers that have received shortage notifications, and manufacturers with shortage-related histories will receive elevated inspection priority.

The integration of shortage data into inspection prioritization is a significant development for peptide manufacturers because it means that supply problems, even those reported in good faith under the new notification requirements, can trigger increased FDA regulatory attention. Manufacturers should ensure that shortage notifications are accompanied by robust mitigation plans and that their manufacturing documentation and quality systems can withstand the scrutiny that elevated inspection priority may bring.

Compliance Readiness Recommendations

Peptide manufacturers preparing for the new shortage reporting framework should focus on several priority areas: updating written shortage monitoring and notification procedures to reflect the six-month advance window and earliest-knowledge trigger; implementing formal quarterly supply risk reviews that assess shortage risk across all marketed products; establishing the technical infrastructure and trained personnel to use the new DSRS electronic reporting system; and reviewing contracts with CDMOs and API suppliers to ensure that supply disruption information flows to the finished product manufacturer's regulatory team in time to meet notification deadlines.

The 120-day enforcement discretion period following the July 1, 2026 DSRS go-live date provides some transition flexibility, but manufacturers that have not established DSRS capabilities before enforcement discretion expires in late October 2026 will face significant risk of violation citations if a shortage notification obligation arises during or after that period.